OPKO Health, Inc. (OPK) Stock Price & Analysis
OPKO Health, Inc. (OPK) closed at USD 1.61 on Thursday, October 15, 2026, up 17.52% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.37; the Oct 15, 2026 session ranged USD 1.48–1.7 on volume of 55,304,776 shares. Market capitalization is $1.20B, with a 52-week range of USD 0.98–1.75 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OPK.md
Key facts (OPK)
- Last four reported quarters (through Jun 30, 2026): revenue $588M, net income -$72.9M (-12.4% margin), free cash flow -$134M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 4.38 (range 3–8.5).
- Total return with dividends: 1Y +7.3% vs S&P 500 +18.1%; 5Y -56.7% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD -0.06, revenue estimate $137M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OPK)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.77B | $1.00B | $863M | $713M | $607M | $588M |
| Gross profit | — | $288M | $318M | $219M | $206M | — |
| Operating income | $18.8M | -$226M | -$157M | -$152M | -$117M | -$48.3M |
| Net income | -$30.1M | -$328M | -$189M | -$53.2M | -$226M | -$72.9M |
| EPS (diluted) | -$0.05 | -$0.46 | -$0.25 | -$0.08 | -$0.30 | — |
| Free cash flow | $6.2M | -$120M | -$44.5M | -$208M | -$191M | -$134M |
| Gross margin | — | 28.7% | 36.8% | 30.6% | 33.9% | — |
| Operating margin | 1.1% | -22.5% | -18.2% | -21.3% | -19.3% | -8.2% |
| Net margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% | -12.4% |
| Revenue growth | +23.6% | -43.4% | -14.0% | -17.4% | -14.9% | — |
| Cash + short-term investments | $135M | $153M | $95.9M | $427M | $364M | — |
| Total debt | $205M | $11.0M | $9.7M | $440M | $4.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OPK)
P/S 2.0x · EV/EBITDA 21.8x · EV/Sales 1.5x · P/B 1.0x · FCF yield -11.15% · Earnings yield -6.07% · Buyback yield (TTM) 3.88% · Net cash $298M · EV $904M
Analysts (OPK)
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 4.38 (low 3, high 8.5).
Total return (dividends reinvested) (OPK)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +7.3% | -56.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +7.4% | -15.4% |
| Volatility (annualized) | 55.0% | 57.1% |
| Max drawdown | -28.1% (Oct 2025→Mar 2026) | -81.5% (Dec 2021→Jan 2024) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 1.61 |
|---|---|
| Change | ▲ 17.52% (up) |
| Previous Close | USD 1.37 |
| Open | USD 1.65 |
| Day Range | USD 1.48 – 1.7 |
| 52-Week Range | USD 0.98 – 1.75 |
| Volume | 55,304,776 shares |
| Market Cap | $1.20B |
| Exchange | NMS |
Technical Analysis (OPK)
Nexqual's technical model rates OPK "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.34 (neutral) |
| vs SMA50 | Above (USD 1.51) |
| MACD | -0.03 (negative) |
Analyst Ratings (OPK)
Wall Street analysts rate OPK "Buy" based on 6 analysts, with a mean price target of USD 4.38 (range USD 3–8.5), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 4.38 |
| High Target | USD 8.5 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (OPK)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $136.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.03 vs est -0.11 ▲ beat |
| 2026-03-31 | USD -0.07 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.04 vs est -0.07 ▲ beat |
| 2025-09-30 | USD 0.03 vs est -0.05 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (OPK)
| Total Revenue | $587.90M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.30% |
| Gross Margin | +19.47% |
| Operating Margin | -15.31% |
| Profit Margin | -12.40% |
| ROE | -5.88% |
| Debt / Equity | 0.34 |
| Current Ratio | 3.35 |
| Total Cash | $300.76M |
| Total Debt | $398.08M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$190.82M (-31.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (OPK)
Nexqual rates OPKO Health, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 19%, operating -15% |
| Balance Sheet | Strong — $301M cash vs $398M debt |
| Cash Flow | Weak — FCF negative: -$191M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -6%, ROA -5.5% |
Ownership (OPK)
| Insider Ownership | +50.52% |
|---|---|
| Institutional Ownership | +27.56% |
| Shares Outstanding | 746.33M |
| Float | 323.73M |
| Short % of Float | +8.57% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (OPK)
OPKO Health, Inc. is led by Phillip Frost (age 89), Chairman of the Board & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman of the Board & CEO | Phillip Frost (age 89) |
|---|---|
| Vice Chairman of the Board & Chief Technical Officer | Jane H. Hsiao (age 78) |
| President & Vice Chairman of the Board | Elias Adam Zerhouni (age 74) |
| Senior VP, CFO, Chief Accounting Officer & Treasurer | Adam E. Logal (age 47) |
| Executive VP of Administration & Director | Steven D. Rubin Esq. (age 65) |
Major Backers & Investors (OPK)
Notable institutional backers of OPKO Health, Inc. include Rubric Capital Management LP, Goldman Sachs, UBS Group AG, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 6.4% |
| Goldman Sachs | 0.94% |
| UBS Group AG | 0.67% |
| Whitefort Capital Management, LP | 0.6% |
| Fidelity | 0.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.48% |
| BlackRock | 7.22% |
| Geode Capital | 1.55% |
| State Street | 1.38% |
| Northern Trust | 0.5% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FRNM | Freenome, Inc. | USD 12.29 | ▼ 2.81% |
| CSTL | Castle Biosciences, Inc. | USD 33.8 | ▲ 2.8% |
| PSNL | Personalis, Inc. | USD 15.93 | ▲ 0.5% |
| WGS | GeneDx Holdings Corp. | USD 70.22 | ▲ 8.1% |
| NEO | NeoGenomics, Inc. | USD 17.25 | ▲ 3.54% |
| FLGT | Fulgent Genetics, Inc. | USD 21.34 | ▲ 1.33% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt